ReviewCurrent oncology (Toronto, Ont.)2023
Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options.
Review in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed.
- Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.Nature cancer · 2026Trial
- MYBL2 promotes malignant phenotypes and M2-like macrophage polarization through CCL2 in non-small cell lung cancer.Molecular and cellular biochemistry · 2026Article
- Machine learning-based mapping of multimodal treatment allocations and prognostic implications of clinical concordance in non-small cell lung cancer.Scientific reports · 2026Article
- Multidisciplinary Team Care for Early-Stage Lung Cancer in Low- and Middle-Income Countries and Emerging Economies: Current Position and Call for Action.Thoracic cancer · 2026Review
- RATIONALE-303: Long-Term Outcomes of Tislelizumab in Previously Treated Advanced/Metastatic NSCLC.JTO clinical and research reports · 2026Article
- Immune-preserving radiotherapy and perioperative immunotherapy in stage III NSCLC: a narrative review of current management and future directions for IIIA/IIIB NSCLC.Translational lung cancer research · 2026Review
- Nationwide Implementation of Neoadjuvant Nivolumab-Based Chemo-Immunotherapy for Resectable NSCLC: Surgical Outcomes from a Prospective Multicenter Study.Annals of surgical oncology · 2026Article
- Article
- Debate: why surgery should remain central in the management of locally advanced (Stage III) non-small-cell lung cancer.BJC reports · 2026Article
- Tumor stage, squamous histology and male sex predict positive resection margins in non-small cell lung cancer patients undergoing anatomical resection-a retrospective study from a high-volume thoracic surgery unit.Journal of thoracic disease · 2026Article
- A plant alkaloid lycorine inhibits non-small cell lung cancer cell proliferation, metastasis, glycolysis and promotes ferroptosis through the ZNF143/SPC25 axis.Journal of natural medicines · 2026Article
- Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy.Clinical and translational radiation oncology · 2026Article
- Epithelial Integrins Coordinate Cellular Crosstalk Through the Regulation of Cytokines During Tissue Remodeling.International journal of molecular sciences · 2026Review
- Comparing the Prognosis of Non-Small Cell Lung Cancer Patients Who Did Not Undergo Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy: A Retrospective Study.Thoracic cancer · 2026Article
- First-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 Trials.JTO clinical and research reports · 2026Article
- The emerging role of exosomal circRNAs in modulating apoptotic pathways and overcoming cancer therapy resistance.Discover oncology · 2026Review
- Proton Versus Photon Radiotherapy for Non-Small Cell Lung Cancer: Updated Evidence from a Systematic Review and Meta-Analysis.Cancers · 2026Review
- Leveraging CT-based online adaptive radiotherapy for dose escalation in hypofractionated radiotherapy for locally advanced unresectable lung cancer.Frontiers in oncology · 2026Article
- Upfront Surgery for c-Stage IIIB Non-Small Cell Lung Cancer with an Abnormally High Preoperative Serum Carcinoembryonic Antigen Level: A Case Report.Surgical case reports · 2026Article
- Effectiveness and safety of carbon ion radiotherapy for stage III non-small cell lung cancer: a single-center retrospective study.Frontiers in oncology · 2026Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the second-most commonly diagnosed cancer and the leading cause of cancer death worldwide. The most common histological type is non-small-cell lung cancer, accounting for 85% of all lung cancer cases. About one out of three new cases of non-small-cell lung cancer are diagnosed at a locally advanced stage-mainly stage III-consisting of a widely heterogeneous group of patients presenting significant differences in terms of tumor volume, local diffusion, and lymph nodal involvement. Stage III NSCLC therapy is based on the pivotal role of multimodal treatment, including surgery, radiotherapy, and a wide-ranging option of systemic treatments. Radical surgery is indicated in the case of hilar lymphnodal involvement or single station mediastinal ipsilateral involvement, possibly after neoadjuvant chemotherapy; the best appropriate treatment for multistation mediastinal lymph node involvement still represents a matter of debate. Although the main scope of treatments in this setting is potentially curative, the overall survival rates are still poor, ranging from 36% to 26% and 13% in stages IIIA, IIIB, and IIIC, respectively. The aim of this article is to provide an up-to-date, comprehensive overview of the state-of-the-art treatments for stage III non-small-cell lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.